Saturday, August 31, 2013

Quintiles Executives to Present at Baird Healthcare Conference

Me Newswire / Business Wire

RESEARCH TRIANGLE PARK, N. - Saturday, August 31st 2013

Quintiles CEO Tom Pike and Chief Financial Officer Kevin Gordon will present at the Baird Healthcare Conference on Tuesday, September 10, 2013 in New York, NY at the New York Palace.

The Quintiles presentation will begin at 1:45 p.m. EDT. A link to live audio of the Quintiles presentation will be posted in the Event Calendar of Quintiles’ website, An archived audio version of the presentation will be available later that day.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit

Click here to subscribe to Mobile Alerts for Quintiles.



Phil Bridges, Media Relations


Karl Deonanan, Investor Relations



PerkinElmer Offers First Commercially Available Newborn Screen for Severe Combined Immunodeficiency (SCID) in Europe & the Middle East

SCID screening improves medical outcomes with early detection, intervention

WALTHAM, Mass - Thursday, August 29th 2013 [ME NewsWire]

(BUSINESS WIRE) PerkinElmer, Inc., a global leader in improving the health and safety of people and the environment, today introduced the first commercially available screening test for Severe Combined Immunodeficiency (SCID). The EnLite™ Neonatal TREC System expands the newborn screening portfolio of commercially available tests and will be introduced under CE marking, for sale in select countries in Europe and the Middle East.

SCID impacts an estimated 1 in 50,000 to 1 in 100,000 newborns globally every year. The disease is a genetic disorder that can reduce lifespan but it can be treated when detected early in newborns. Treatments include bone marrow or cord blood transplant (BMT/CBT) from a family member or donor. PerkinElmer’s new SCID screening test provides a benefit over current laboratory tests by reducing steps in the workflow, thus increasing screening efficiency.

Implementing screening for early detection of SCID as part of a newborn screening program provides a cost benefit compared to the greater costs of managing the disease when detected later. This is due to fewer complications that require prolonged and intensive care as a result of the earlier detection and diagnosis of SCID.

“PerkinElmer has been a global leader in newborn screening for more than 25 years. Our new SCID screening test is the direct result of our extensive expertise, knowledge and commitment to ensuring that newborn screening laboratories have access to the most advanced testing products for improving the health of babies,” said Jim Corbett, president, Diagnostics and Life Sciences and Technology, PerkinElmer. “We are pleased to offer this new screening test to many countries in Europe and the Middle East so that they can incorporate it as part of their pre-existing newborn screening programs for early detection of this genetic disorder and timely clinical intervention for improved medical outcomes.”

“We have seen that early clinical intervention is key to allowing effective management for patients with Severe Combined Immunodeficiency,” said Bobby Gaspar, M.D, Ph.D., Professor of Pediatrics and Immunology at London’s Great Ormond Street Hospital for Children and the UCL Institute of Child Health. “With the availability of PerkinElmer’s new test for screening SCID, clinicians will be able to diagnose patients more quickly and precisely, improving quality of life and transplant outcome for newborns affected by this highly debilitating and potentially fatal condition.”

Screening through the EnLite™ Neonatal TREC System is intended to provide accurate results and minimize the number of steps taken towards a SCID diagnosis. The simplified procedure is designed to be cost effective and fit within the existing newborn screening processes that are utilized by laboratories. The test has been designed to minimize manual work and the risk of contamination by reducing the number of transfer steps. The test includes software-aided traceability for the workflow that is intended to improve safety and efficacy in the screening use.

To learn more about PerkinElmer’s newborn screening platforms, visit:

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at Join the conversation and follow us on twitter at

About Great Ormond Street Hospital for Children NHS Foundation Trust

The UCL Institute of Child Health, in partnership with Great Ormond Street Hospital (GOSH), is the largest centre in Europe devoted to clinical and basic research and postgraduate teaching in children’s health. Academics at the UCL Institute of Child Health work together with clinicians at GOSH to form an integrated and multi-disciplinary approach to the understanding, diagnosis, treatment and prevention of childhood disease. Many individuals hold joint appointments at both institutions. This allows the hospital and the institute to work together to translate research undertaken in laboratories into clinical trials and treatments in the hospital, bringing real benefits to the children at GOSH and to the wider paediatric community. See for more information.


Edelman (On behalf of PerkinElmer, Inc.)

Jen Reid, 404-460-8587


Quintiles Executives to Present at Morgan Stanley Global Healthcare Conference

ME NewsWire / BusinessWire

RESEARCH TRIANGLE PARK, N.C - Thursday, August 29th 2013

Morgan Stanley Global Healthcare Conference 2013

Quintiles CEO Tom Pike and Chief Financial Officer Kevin Gordon will present at the 2013 Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013 in New York, NY at the Grand Hyatt New York.

The Quintiles presentation will begin at 9:25 a.m. EDT.  A link to live audio of the Quintiles presentation will be posted in the Event Calendar of Quintiles’ website,  An archived audio version of the presentation will be available later that day.

About Quintiles

Quintiles (NYSE:Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit

Click here to subscribe to Mobile Alerts for Quintiles.



Phil Bridges, + 1 919-998-1653

Media Relations

Karl Deonanan, +1 919-998-2789

Investor Relations


Press Alert: Boehringer Ingelheim to Raise Awareness of Women in Cardiovascular Disease and Thrombosis

ME NewsWire / Business Wire

INGELHEIM, Germany - Friday, August 30th 2013

For media outside of the US, the UK & Canada only

What: Join key experts in cardiology and thrombosis for a special TweetChat (#ChatAFib), live from the ESC Congress 2013 (#ESCcongress2013) in Amsterdam, which is organised by the European Society of Cardiology

We will be discussing:

    Key issues around awareness of cardiovascular disease and thrombosis in women
    How common is antithrombotic treatment use in women versus men?
    Are women more likely than men to become disabled by an AF-related stroke?
    Management of women, cardiovascular disease and thrombosis in daily clinical practice


    Prof. Angela Maas, Professor of Cardiology for Women, UMC, St. Radboud, The Netherlands
    Dr. Yolande Appelman, Chair of the Working Group on Gender, The Netherlands Society of Cardiology and Interventional Cardiologist at VUmc
    Patient Advocacy Group representatives including Mellanie True Hills from and De Hart & Vaatgroep

When: 15:00 - 16:00 CET, Monday 2nd September

How: This is a bilingual TweetChat. To join the conversation in English follow #ChatAFib, to join the conversation in Dutch follow #Hartenvaat

On Twitter

Follow @boehringer and @boehringernl for updates and information


Boehringer Ingelheim GmbH

Sara McClelland

Corporate Communications

Media + PR

Phone: +49 6132 – 77 8271

Fax: + 49 - 6132 – 72 6601



More information


Thursday, August 29, 2013

Mavenir Announces Commercial Deployment of Virtualized RCS Based on NFV

ME Newswire / Business Wire

RICHARDSON, Texas & LONDON - Thursday, August 29th 2013

Mavenir Systems®, a leading provider of software-based mobile communications solutions, announced today that it has launched a commercial deployment of virtualized Rich Communication Services (RCS-e) in a multi-tenant Network Functions Virtualization (NFV) environment.

Mavenir has demonstrated significant CAPEX reductions for IMS-based RCS deployments when utilizing multi-tenancy on a centrally deployed common platform. Mobile operators are leveraging NFV technologies to build and manage their next generation networks in a more efficient and cost effective manner that will also enable increased network flexibility and service velocity. A recent survey by TelecomTV Futures1, in association with HP and Intel, indicated that 78% of respondents rated NFV as either ‘important’ or ‘very important’ to service provider success in the future.

“We are seeing increased pressure on mobile operators to reduce the cost and complexity of network service deployment creating a market for disruptive transformation with more efficient NFV based networks,” said Pardeep Kohli, President and CEO, Mavenir Systems. “Many of our customers are already seeing the agility and the benefits of Virtualized IMS in their live networks, not just in lab trials.”

Utilizing Mavenir’s previously announced Virtualized IMS platform, leading Tier-1 operators in Europe are currently rolling out Mavenir's NFV technology as part of their VoLTE /RCS rollouts. The commercial deployment of RCS-e services in a virtualized, multi-tenant environment was launched in 2013 to serve subscribers across multiple countries.

Mavenir is leveraging its virtualization technology to provide the multi-tenancy capability needed by multi-national mobile operator groups. Importantly, virtualization also provides the capacity elasticity and operational flexibility to allow traffic pattern shifts from legacy messaging to IP messaging services.


1 TelecomTV Survey July 2013

About Mavenir:

Mavenir is a leading provider of software-based communications solutions that enable mobile service providers to deliver high-quality internet protocol (IP)-based voice, video, rich communication and enhanced messaging services to their subscribers globally. Mavenir’s mOne® software platform has enabled leading mobile service providers to introduce the industry’s first live network deployment of Voice-Over-LTE (VoLTE) and the industry’s first live deployment of next-generation Rich Communication Services 5.0 (RCS). Our solutions deliver next-generation services such as RCS, VoLTE and Voice over Wi-Fi (VoWi-Fi) over existing 2G and 3G networks and next-generation 4G LTE networks.

© 2013 Mavenir Systems, Inc. All rights reserved.

Mavenir Systems®, mOne®, AirMessenger®, Mavenir™, mStore™ and mCloud™, Transforming Mobile Networks™, are trademarks of Mavenir Systems, Inc.



Maryvonne Tubb, 972-333-7282


Toshiba Celebrates Opening of New Semiconductor Facility in Thailand

-- To relocate discrete assembly to new site --

BANGKOK & TOKYO - Thursday, August 29th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO:6502) today announced that its Thai-based Group company, Toshiba Semiconductor (Thailand) Co., Ltd.(TST), has completed its relocation to a new semiconductor manufacturing facility and started mass production, marking the company’s full recovery from the devastating flooding of 2011.

The new factory is some 140km north-east of Bangkok, a state-of-the art facility in the 304 Industrial Park in Prachinburi. Construction started in July 2012, limited production began this April, and the facility is now operating at its current target capacity. At 1.4 times the size of the flood-damaged plant, the new facility and its cutting-edge production equipment will allow TST and Toshiba Group to secure greater operating efficiency and higher productivity, while at the same time offering room for expansion that will allow the company to respond quickly and flexibly to growth in market demand.

TST carries out back-end processes, the assembly and packaging of small signal devices and photocouplers, both product areas where strong demand growth is anticipated. Small signal devices control current and voltage in digital consumer products and are essential components of such popular products as smart phones and tablets, and photocouplers are widely used in industrial products, including inverters.

Commenting on the new plant, Mr. Yasuo Ashizawa, president of TST said, “We are all delighted that the new plant is now up and running. I thank the Thai authorities for all the support we have received for our relocation, the construction company for its dedication and efficiency, and, most of all, our employees, who have stayed with, made the move to this new plant and made every effort to get it up and running. We have rebuilt capacity with more modern, more productive equipment, and we look forward to supporting a new round of expansion in Toshiba Group’s discrete business.”

TST was forced to halt production in October 2011 when its factory in the Bangkadi Industrial Park in Patumtani, immediately north of Bangkok, was inundated by flood waters. During this forced suspension of operations, Toshiba transferred production to its facilities in Japan and Malaysia, and utilized outsourcing. With the opening of the new TST facility, Toshiba plans to gradually reintegrate these relocated operations.

Toshiba Group is revitalizing its discrete device business by boosting efficiency to secure improved profitability. Measures to date include adopting to larger wafers and securing higher output in the front-end process, and accelerating the overseas transfer of the back-end process. The new TST facility will improve cost competitiveness in the back-end process, strengthen the bottom line and contribute to the overall strength of the discrete business unit.

Outline of Toshiba Semiconductor (Thailand) Co., Ltd.


Prachinburi prefecture, Thailand


Approx. 500


October 1990


Yasuo Ashizawa, President

Site Area:

Approx. 135,000m2

Floor area:

Approx. 40,000m2

Production item:

Discrete semiconductors (small signal devices, photocouplers)

About Toshiba

Toshiba is a world-leading diversified manufacturer, solutions provider and marketer of advanced electronic and electrical products and systems. Toshiba Group brings innovation and imagination to a wide range of businesses: digital products, including LCD TVs, notebook PCs, retail solutions and MFPs; electronic devices, including semiconductors, storage products and materials; industrial and social infrastructure systems, including power generation systems, smart community solutions, medical systems and escalators & elevators; and home appliances.

Toshiba was founded in 1875, and today operates a global network of more than 590 consolidated companies, with 206,000 employees worldwide and annual sales surpassing 5.8 trillion yen (US$61 billion). Visit Toshiba's web site at

Toshiba in Thailand

Toshiba opened its first office in Thailand 50 years ago, in 1963, and since then has provided the Thai market with a range of consumer products. Toshiba manufactures home appliances and electronic devices in the Thailand. Responding to the Southeast Asia’s continued development and growing demand, Toshiba reinforced its infrastructure business function in Thailand in May 2013, so as to offer comprehensive support for major projects in Thailand and the wider region.

Photos/Multimedia Gallery Available:


Toshiba Corporation

Semiconductor & Storage Products Company

Megumi Genchi / Kota Yamaji, +81-3-3457-3576

Communication IR Promotion Group

Business Planning Division


Gemalto First Semester 2013 Results

AMSTERDAM - Thursday, August 29th 2013 [ME NewsWire]

    Record first semester with revenue at € 1.13 billion, up +13%
    Platforms & Services revenue up +25% to €208 million
    Profit from ongoing operations up +14%

To better assess past and future performance, the income statement is presented on an adjusted basis (see page 2 “Basis of preparation of financial information”). Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable IFRS measures and should be read only in conjunction with the consolidated financial statements. The reconciliation with the IFRS income statement is presented in Appendix 2. The statement of financial position is prepared in accordance with IFRS, and the cash position variation schedule is derived from the IFRS cash flow statement. All figures in this press release are unaudited.

(BUSINESS WIRE) Regulatory News:

Gemalto (Euronext NL0000400653 - GTO), the world leader in digital security today announces its results for the first semester 2013.

Key figures of the adjusted income statement

Year-on-year variations

Ongoing operations1 (€ in millions)

First semester 2013

First semester 2012

at historical exchange rates

at constant exchange rates






Gross profit




Operating expenses




Profit from operations




Profit margin



+0.3 ppt

Olivier Piou, Chief Executive Officer, commented: “Gemalto recorded another strong semester of profitable growth, more than offsetting increased investments in operations made in the second part of last year. Over the period, our teams continued to deploy milestone programs and we are on track to meet our objectives for 2013. The announcement next week of our new development plan will provide company’s stakeholders with Gemalto’s blueprint to leverage the expanding opportunities we have in front of us.”

1 See basis of preparation on page 2, and Appendix 1 of this document for more information on ongoing operations.

Basis of preparation of financial information

In this press release, the information for the first semester of both 2013 and 2012 is presented for “ongoing operations” and under the 2013 format of segment reporting unless otherwise specified

Adjusted income statement and profit from operation (PFO) non-GAAP measure

The interim condensed consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (IFRS).

To better assess its past and future performance, the Company also prepares an adjusted income statement where the key metric used to evaluate the business and take operating decisions over the period 2010 to 2013 is the profit from operations.

Profit from operations (PFO) is a non-GAAP measure defined as the IFRS operating result adjusted for the amortization and depreciation of intangibles resulting from acquisitions, for share-based compensation charges, and for restructuring and acquisition-related expenses. These items are further explained as follows:

    Amortization and depreciation of intangibles resulting from acquisitions are defined as the amortization and depreciation expenses related to the intangibles recognized as part of the allocation of the excess purchase consideration over the share of net assets acquired.
    Share-based compensation charges are defined as (i) the discount granted to employees acquiring Gemalto shares under Gemalto Employee Stock Purchase plans; and (ii) the amortization of the fair value of stock options and restricted share units granted by the Board of Directors to employees, and other related costs.
    Restructuring and acquisitions-related expenses are defined as (i) restructuring expenses which are the costs incurred in connection with a restructuring as defined in accordance with the provisions of IAS 37 (e.g. sale or termination of a business, closure of a plant,…), and consequent costs; (ii) reorganization expenses defined as the costs incurred in connection with headcount reductions, consolidation of manufacturing and offices sites, as well as the rationalization and harmonization of the product and service portfolio, and the integration of IT systems, consequent to a business combination; and (iii) transaction costs (such as fees paid as part of the acquisition process).

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable IFRS measures and should be read only in conjunction with our interim condensed consolidated financial statements prepared in accordance with IFRS.

In the adjusted income statement, Operating Expenses are defined as the sum of Research and Engineering, Sales and Marketing, General and Administrative expenses, and Other income (expense) net.

EBITDA is defined as PFO plus depreciation and amortization expenses, excluding the above amortization and depreciation of intangibles resulting from acquisitions.

The Appendix 2 bridges the adjusted income statement to the IFRS income statement.

Ongoing operations

For a better understanding of the current and future year-on-year evolution of the business, the Company provides an adjusted income statement for “ongoing operations” for both 2013 and 2012 reporting periods.

The adjusted income statement for ongoing operations excludes, as per the IFRS income statement, the contribution from discontinued operations to the income statement, and also the contribution from assets classified as held for sale and from other items not related to ongoing operations.

For the first semester 2013, reported figures for ongoing operations only differ from figures for all operations by the contribution from assets held for sale, considered non-strategic and currently being disposed.

Appendix 1 bridges the adjusted income statement for ongoing operations to the adjusted income statement for all operations.

Historical exchange rates and constant currency figures

Revenue variations are at constant exchange rates, except where otherwise noted.

All other figures in this press release are at historical exchange rates, except where otherwise noted.

The Company sells its products and services in a very large number of countries and is commonly remunerated in other currencies than the Euro. Fluctuations in these other currencies exchange rates against the Euro have in particular a translation impact on the reported Euro value of the Company revenues. Comparisons at constant exchange rates aim at eliminating the effect of currencies translation movements on the analysis of the Group revenue by translating prior-year revenues at the same average exchange rate as applied in the current year.

IFRS results

The interim condensed consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS). To better assess its past and future performance, the Company also prepares an adjusted income statement. Appendix 2 provides the reconciliation between IFRS and adjusted income statements.

Gemalto’s IFRS income statement for the first semester 2013 shows an operating profit (EBIT) of €104 million. This profit is up +38% on the first semester of 2012.

Restructuring and acquisition-related expenses amounted to €0.7 million (€2.4 million in the first semester of 2012). The equity-based compensation charge was €13 million (€25 million in the first semester of 2012) and amortization and depreciation of intangibles resulting from acquisitions amounted to €13 million (€10 million in the same period of 2012).

As a result, the IFRS net profit also showed a strong increase, up +38% over the first semester of 2012 to €81 million.

IFRS basic earnings per share and diluted earnings per share showed the same strong year-on-year increase. At €0.96 and €0.94 respectively for the reported period, IFRS basic earnings per share were higher by +36% and IFRS diluted earnings per share were higher by +39% when compared to the corresponding figures of the first semester of 2012.

To view the full release including the tables, please click here


Investor Relations

Gabriel Rangoni, +33 6 1426 6956

John Lineberger, +33 6 1243 6304

Corporate Communication

Isabelle Marand, +33 6 1489 1817

Media Relations Agency

Citigate FF

Suzanne Bakker, +31 6 1136 8659


Edi Cohen, +31 6 2151 7820

Wednesday, August 28, 2013

Procter & Gamble Provides Educational Grant to Support World Dental Posters

New Site Allows for Important Scientific Information to be Shared Publicly

CINCINNATI - Tuesday, August 27th 2013 [ME NewsWire]

(BUSINESS WIRE) Procter & Gamble (P&G), the makers of Crest and Oral-B, along with Stephen Hancocks Limited announced today that the open-access, scientific site, World Dental Posters (, will now be sponsored through an educational grant from P&G.

World Dental Posters is an open access site launched in March 2013 that provides scientific researchers the opportunity to upload their peer-reviewed posters at no cost for as long as they wish. Typically, peer-reviewed posters are presented at industry congresses, conferences and meetings or through subscription-based journals – this site gives the authors another channel to present their findings. The site also provides citable references that informed the research, without losing copyright protection for the individual authors.

Philip Giorgi, Managing Director and co-owner of Stephen Hancocks Limited, conceived the idea for World Dental Posters after seeing a pile of posters discarded at numerous international dental conferences and congresses. He realized there was an opportunity to identify a way to keep this research available for others to see around the world.

“We are delighted that P&G shares our vision for this free, open access site created as a way to disseminate research through posters beyond current possibilities,” said Philip Giorgi. “Providing researchers with the opportunity to connect and share their ideas and findings is a fundamental cornerstone of scientific advancement.”

“As a company, we are passionate about research in the development of our products and technologies,” said Dr. Leslie Winston of P&G Global Oral Care Professional & Scientific Relations. “We are, therefore, pleased to support World Dental Posters with a grant as a way to allow, in particular, young and innovative researchers in the field of oral health to disseminate their findings and discover others working in similar areas.”

Posters uploaded on to the World Dental Posters site are indexed by title, author name(s) and key words and can remain on the site for free for as long as the author(s) wish. Future developments will include forum and discussion areas for connecting researchers with similar interests and ideas from different geographic locations who might otherwise be unaware of each other’s work.

About Stephen Hancocks Limited

Stephen Hancocks Limited is a well established publishing company specializing in dental books, journals and continuing education materials in print and online for the dental team. The website ( has over 40,000 registered regular users who access the products and services particularly through the innovative dental digest identNEWS (

About Crest

A trusted leader in oral health, Crest was the first oral care brand to secure the ADA Seal of Acceptance for a clinically proven fluoride toothpaste. Since first introducing fluoride toothpaste 54 years ago, it is estimated that Crest has helped prevent more than half a billion cavities in the United States. Headquartered in Cincinnati, OH, Crest is owned and distributed by Procter & Gamble.

About Oral-B

Oral-B is the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand includes manual and electric toothbrushes for children and adults, oral irrigators and interdental products, such as dental floss. Oral-B manual toothbrushes are used by more dentists than any other brand in the U.S. and many international markets.

About Procter & Gamble

P&G serves approximately 4.8 billion people around the world with its brands. The Company has one of the strongest portfolios of trusted, quality, leadership brands, including Ace®, Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Duracell®, Fairy®, Febreze®, Fusion®, Gain®, Gillette®, Head & Shoulders®, Iams®, Lenor®, Mach3®, Olay®, Oral-B®, Pampers®, Pantene®, Prestobarba®, SK-II®, Tide®, Vicks®, Wella®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit for the latest news and in-depth information about P&G and its brands.



Alexandra Tadeu, 646-500-7842


Live Webcast of Gemalto's New Multi-Year Development Plan

AMSTERDAM - Wednesday, August 28th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Regulatory News:

Gemalto (Euronext NL 0000400653 GTO), the world leader in digital security, is pleased to remind that its new multi-year strategic development plan and business objectives will be presented on September 5th, 2013, through a live webcast, starting at 7:00 PM Amsterdam and Paris time, 6:00 PM London time, 1:00 PM New York time.

The live webcast, accessible at, will start with an around two-hour presentation of the new plan by the Company executives. This presentation will be followed by an approximately one-hour Questions and Answers session, which will start at 9:30 PM Amsterdam and Paris time, 8:30 PM London time, 3:30 PM New York time, also accessible through the live webcast.

The associated presentation document will be made available on the investors section of Gemalto's website at right after the event.

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the world leader in digital security with 2012 annual revenues of €2.2 billion and more than 10,000 employees operating out of 83 offices and 13 Research & Development centers, located in 43 countries.

We are at the heart of the rapidly evolving digital society. Billions of people worldwide increasingly want the freedom to communicate, travel, shop, bank, entertain and work – anytime, everywhere – in ways that are enjoyable and safe. Gemalto delivers on their expanding needs for personal mobile services, payment security, authenticated cloud access, identity and privacy protection, eHealthcare and eGovernment efficiency, convenient ticketing and dependable machine-to-machine (M2M) applications. We develop secure embedded software and secure products which we design and personalize. Our platforms and services manage these products, the confidential data they contain and the trusted end-user services made possible.

Our innovations enable our clients to offer trusted and convenient digital services to billions of individuals. Gemalto thrives with the growing number of people using its solutions to interact with the digital and wireless world.

For more information visit,,, or follow @gemalto on Twitter.


Investor Relations

Gabriel Rangoni, +33 6 1426 6956

Investor Relations

Gabriel Rangoni, +33 6 1426 6956

Corporate Communication

Isabelle Marand, +33 6 1489 1817

Media Relations Agency

Citigate FF

Suzanne Bakker, +31 6 1136 8659


Edi Cohen, +31 6 2151 7820

Decoo, Inc. Launches 'Decoppa!' Anyone Can Easily Create Cute Caricatures with This Free App Available from the App Store and Google Play

TOKYO - Wednesday, August 28th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Decoo, Inc. announces the release of the free smartphone caricature building app ‘Decoppa!’, available from Aug. 28, 2013 at the App Store and Google play.

The 'Decoppa!' app enables users to combine selected parts to form their very own caricature. Build caricatures of yourself, family, friends, celebrities - the choices are unlimited. Naturally, you can upload your creations to Twitter and Facebook. If you choose to save your images, they can also be utilized for anything from profile pics to wallpaper. You can create original icons and wallpaper that set you apart from everyone else!

Promotional clips at:

About Decoppa!

-- Choose the parts you want!

From cute to funny, there are over a thousand parts that span a huge spectrum of tastes from which to choose! Nowhere else can you find this volume of choice, and all of these parts are available to you completely free of charge! The basic building blocks of eyes, noses, hairstyles are available, as well as accessories, letters, background parts, and more. Use these to make decorated-photo style kawaii caricatures!

-- Individual parts are editable!

Fine-tune your parts with full control over scaling, rotation, angle, color change, and more. The editor feature gives you the tools to create caricatures that are as close to your imagination as possible.

-- Use them as your SNS icon!

Lots of people are using the caricatures as their profile icon. This app is recommended for users who are hesitant about using their private photos for their Twitter or Facebook account, as well as users how want to have cute icons that really stand out.

-- Surprise your family and friends with a caricature for them!

The range of caricatures using Decoppa is limitless! Beyond family and friends, include popular artists, celebrities, and more. You can bet that a gift to them of their custom caricature will bring a smile to their face!


Release Date:

August 28, 2013






iOS6.0 or later, Android2.4 or later


English, Japanese, Korean



Decoo, Inc. Shibuya Center Place 7F, 1-16-3 Dougenzaka, Shibuya-ku, Tokyo, JAPAN Taikou Yamada, CEO

Photos/Multimedia Gallery Available:


Decoo, Inc.

Kyoji Iino, +81-3-6868-3631


Cegedim Relationship Management Launches New Version of Organization Manager, a CRM-Agnostic Tool that Enables Advanced, Multi-Country Territory and Sales Force Alignments

Latest Release Showcases Enhanced Configuration, Impact Analysis and Tablet Field User Touch Interface

PARIS - Tuesday, August 27th 2013 [ME NewsWire]

(BUSINESS WIRE) -- Cegedim Relationship Management today announced the 9th version of Organization Manager, the CRM-agnostic application that accelerates and optimizes sales territory alignment processes. This solution includes deeper configuration tools, additional visual impact analysis capabilities, new administrative functionalities, and a touch interface to further improve the speed and effectiveness of sales force realignment for the Life Sciences industry.

New Release Merges Features for Territory Alignment & Operational Effectiveness

Organization Manager is a fast, flexible tool for territory alignment management, which ensures that commercial teams are spending time with the right prescribers. This cloud-based solution easily supports multi-country companies, and alleviates significant cost and administrative burdens. The dynamic flexibility of the solution allows companies to quickly respond to business changes with everyday realignments based on business rules. Further, Organization Manager centralizes all alignment information into a central repository which seamlessly integrates with other systems, including CRM and HR systems, eliminating costly disruptions and improving accuracy.

Organization Manager’s Powerful New Features Improve Management of Realignments

The ninth release includes the following new features:

    Enriched Configuration – new tools enable screen design and enhanced reporting.
    Extended Impact Analysis – additional capabilities including maps, charts and graphs to deliver visual data representations that facilitate sales force analysis.
    Field User Touch Interface – empowers field users and their management to provide input into their current and future alignments with fully configurable approval workflows.

“We are constantly enriching Organization Manager to drive our position as the solution of choice for global life sciences companies’ multi-country alignments,” said Dario Ghoddousi, Senior Vice President of Global Sales and Marketing, Cegedim Relationship Management. “We aim to stand out in the space by not offering consulting and additional services for territory alignments, but rather a single configurable tool to enable home office users with the power to independently manage their own activity. By adding new configuration capabilities – commonly offered only through field-based systems – to a home office alignment application, we are elevating the management capabilities for our clients.”

Additionally, the system maintains current, historical, and future alignment data and related views in order to uphold compliance and compensation accuracy. Organization Manager provides integration with any geographical map shape provider - as well as any CRM, SFA, human resources, and other existing systems, including pre-integration with Mobile Intelligence and other Cegedim solutions.

About Cegedim Relationship Management:

Cegedim Relationship Management is the Life Sciences industry’s leading provider of Customer Relationship Management (CRM) solutions. Designed specifically for Life Sciences, the company’s innovative business solutions incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Relationship Management enables more than 200,000 users in many of the world’s most innovative companies to stay ahead of market challenges. In addition to CRM, Cegedim Relationship Management also provides marketing, data optimization and regulatory compliance solutions in more than 80 countries. Cegedim Relationship Management is part of the France-based Cegedim S.A. Group.

To learn more, please visit:

Follow Cegedim Relationship Management on LinkedIn and Twitter.

About Cegedim:

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,100 people in more than 80 countries and generated revenue of €922 million in 2012. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit:

Follow Cegedim on Twitter: @CegedimGroup.


Cegedim Relationship Management

Drew BUSTOS, +1 908-443-2451

Global Communications


Aude BALLEYDIER, +33 (0)1 49 09 68 81

Media Relations

Announcing 'BioJapan 2013' - Asia's Largest Partnering Event for Biotech Businesses

More than 700 companies from Japan and abroad will gather to foster open innovation!

TOKYO - Tuesday, August 27th 2013 [ME NewsWire]

BioJapan 2013 World Business Forum

(BUSINESS WIRE) 'BioJapan 2013 -World Business Forum' will be held from October 9th to 11th, 2013 at Pacifico Yokohama in Exhibition Halls C & D, and the Annex Hall.

BioJapan is an event comprised of exhibitions, seminars, and business partnering meetings geared for the Japanese and global biotechnology industry’s top executives. The theme of this 15th assembly is ‘Towards A New Biotechnology Revolution’. Representatives from biotech industries from various countries will gather here to share technology and information, as well as share ideas for further development.

    More than 700 companies from over 25 countries and regions are expected to participate this year! (a 30% increase from last year) Participants from a wide range of countries and regions have already been confirmed, some of whom will exhibit in large pavilions. Domestic participants include the official sponsors of the event, Chugai Pharmaceutical, Kyowa Hakko Kirin, MSD, and Novartis Pharma, as well as a large number of global pharmaceutical companies, small to medium-sized pharmaceutical companies, bio-ventures, biotech affiliated companies, and domestic research institutions and universities.

    An Updated business matching system! The business matching system has undergone overwhelming improvements, making the process of arranging 'One to One Meetings' more efficient and more effective! This year's business meeting target is 5,000 pairings; a 50% increase over last year’s event. Check the URL below for a list of companies participating in partnering. At the time of writing (Aug. 20th), 444 companies have already registered!

    There will also be over 150 sponsor seminars and presentations from exhibitors! Keynote speeches that will kick off the event will feature Yuko Harayama (Member of the Council for Science and Technology Policy, Cabinet Office, Government of Japan), Lim Chuan Poh (Director at the Agency for Science, Technology Research -Singapore), and Shigetaka Komori (Chairman and CEO, Representative Director of FUJIFILM Holdings Corporation). In addition, seminars from the organizers and exhibitors will address key themes in medical and pharmaceutical technology including regenerative medicine, which is now on the verge of clinical trials, as well as a vast range of topics concerning the environment, energy, healthcare, food and agricultural business, and biotech's industrial base.

    Exhibition Summary

Photos/Multimedia Gallery Available:


Secretariat of BioJapan:

c/o ICS Convention Design, Inc.

Maiko UCHIYAMA, +81-3-3219-3565

Sales Department 3

Tuesday, August 27, 2013

Toshiba Launches High Quality Image Processing IC for LCD TVs

Toshiba Original Super Resolution Circuit and Noise Reduction Contributes to Improvement of Image Quality

TOKYO - Tuesday, August 27th 2013 [ME NewsWire]

(BUSINESS WIRE) Toshiba Corporation (TOKYO:6502) today announced the launch of “TC90232XBG”, a high quality image processing IC for LCD TVs that supports the LVDS input and output for Full HD (1920 x 1080) and WXGA (1366 x 768). Mass production is scheduled to start in December this year.

The IC’s built-in super resolution circuit improves image detail, while an integrated noise reduction function analyzes and detects the edge and flat regions in the image, reducing random noise and mosquito noise, a digital compression artifact that appears near the image edge. A highlight enhancer function to emphasize brightness and brilliance, and an image quality tuning function for color management and gamma correction, are also integrated into the chip. TC90232XBG adds new functionality to LCD TVs and monitors.

Key Features of the Product

1. Toshiba’s original super resolution circuit improves image detail.

2. Built-in noise reduction function reduces random noise and mosquito noise.

3. The highlight enhancer emphasizes image brightness and brilliance.

4. Color management and gamma correction realize proper image quality tuning for a wide range of LCD panels.

5. The widely used I2C BUS control and LVDS standard facilitate easy upgrade of current designs.

6. The IC supports LVDS input and output for Full HD (1920 x 1080) and WXGA (1366 x 768).

7. Small package: 13mm x 13mm.

8. External DDR memory is not required.


Improved picture quality for LCD TVs and monitors

Main Specifications

Part Number


Applicable Panel Resolution

Full HD (1920 x 1080), WXGA (1366 x 768)

(8/10bit, 50/60Hz)

Input Interface

LVDS 2-Link

Output Interface

LVDS 2-Link


FBGA158 (13mmx13mm, 0.8mm Pitch)

Source Voltage


Mass Production

December 2013

Customer Inquiries: Logic LSI Sales & Marketing Group Tel: +81-44-548-2110

Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.

About Toshiba

Toshiba is a world-leading diversified manufacturer, solutions provider and marketer of advanced electronic and electrical products and systems. Toshiba Group brings innovation and imagination to a wide range of businesses: digital products, including LCD TVs, notebook PCs, retail solutions and MFPs; electronic devices, including semiconductors, storage products and materials; industrial and social infrastructure systems, including power generation systems, smart community solutions, medical systems and escalators & elevators; and home appliances.

Toshiba was founded in 1875, and today operates a global network of more than 590 consolidated companies, with 206,000 employees worldwide and annual sales surpassing 5.8 trillion yen (US$61 billion). Visit Toshiba's web site at

Photos/Multimedia Gallery Available:

Media Inquiries:
Toshiba Corporation
Semiconductor & Storage Products Company
Takashi Mochizuki, +81-3-3457-4963


VF to Establish Three Global Innovation Centers to Accelerate Its Innovation Platform

GREENSBORO, N.C. - Tuesday, August 27th 2013 [ME NewsWire]

(BUSINESS WIRE)-- VF Corporation (NYSE: VFC) today announced the company will establish three Global Innovation Centers – a groundbreaking move in the apparel industry – to focus on game-changing product innovations in technical apparel, footwear and jeans.

The centers will be staffed with teams of scientists, engineers, technical designers and key talent who will combine proprietary insights with consumer needs and a deep understanding of technology and new materials. The expected outcome: breakthrough products that drive brand equity and long-term growth.

“These Global Innovation Centers will spark opportunities to fuel VF’s growth and shape the future of apparel and footwear,” said Eric C. Wiseman, Chairman and Chief Executive Officer. “From the mass market to the mountaintop and from the U.S. to South America, Asia and Europe, we will develop and deliver innovative, ‘must-have’ products for consumers.

“Consumers buy and pay more for new, differentiated, value-adding products,” Wiseman continued. “We will inspire consumers to buy our products and, as a result, drive revenue growth and even higher profitability.”

Wiseman also noted that the Innovation Centers are an important step in the further development of VF’s innovation platform. “In 2010, we first laid out our vision for the role that innovation would play in VF’s growth,” he said. “This move is critical to advancing our journey as it gives us a competitive advantage in the apparel industry. We will fully leverage what we learn by sharing output from the Innovation Centers across our 30-plus brands.”

The Technical Apparel Innovation Center will be in Alameda, Calif. The Jeans Center will be in Greensboro, N.C. and the Footwear Center will be in Stratham, N.H. All are expected to be operational during the first half of 2014.

About VF

VF Corporation is a global leader in branded lifestyle apparel and footwear with more than 30 brands. The company’s largest five brands are The North Face®, Vans®, Wrangler®, Timberland® and Lee®. Other brands include 7 For All Mankind®, Bulwark®, Eagle Creek®, Eastpak®, Ella Moss®, JanSport®, Kipling®, lucy®, Majestic®, Napapijri®, Nautica®, Red Kap®, Reef®, Riders®, Splendid® and SmartWool®. For more information, please visit

Forward-Looking Statements

Certain statements included in this release and the attachments are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting VF and therefore involve a number of risks and uncertainties. You can identify these statements by the fact that they use words such as “will” and “expect” and other words and terms of similar meaning or use of future dates. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of VF to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the level of consumer confidence and overall level of consumer demand for apparel; fluctuations in the price, availability and quality of raw materials and contracted products; disruption to VF’s distribution system; disruption and volatility in the global capital and credit markets; VF's reliance on a small number of large customers; the financial strength of VF's customers; VF’s response to changing fashion trends; increasing pressure on margins; VF's ability to implement its growth strategy; VF's ability to grow its international and direct-to-consumer businesses; VF's ability to successfully integrate and grow acquisitions, including the Timberland acquisition; VF's ability to maintain the strength and security of its information technology systems; adverse unseasonable weather conditions; stability of VF's manufacturing facilities and foreign suppliers; continued use by VF's suppliers of ethical business practices; VF's ability to accurately forecast demand for products; continuity of members of VF's management; VF's ability to protect trademarks and other intellectual property rights; maintenance by VF's licensees and distributors of the value of VF's brands; foreign currency fluctuations; changes in tax liabilities; and legal, regulatory, political and economic risks in international markets. More information on potential factors that could affect VF's financial results is included from time to time in VF's public reports filed with the Securities and Exchange Commission, including VF's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.


VF Corporation

Carole Crosslin, 336-424-7836

Director, Corporate Communications

Lance Allega, 336-424-6082

Director, Investor Relations


Sebastian Vettel Announced as Braun's New Global Ambassador

Braun and Vettel join forces to inspire men to make their dreams become reality

KRONBERG, Germany - Tuesday, August 27th 2013 [ME NewsWire]

(BUSINESS WIRE)-- BRAUN today proudly announces triple Formula 1 world champion Sebastian Vettel as the new global ambassador for BRAUN’s male power grooming range. This exciting collaboration also marks the launch of the BRAUN global campaign “Hold on to your Dreams”.

The announcement was made at the Formula 1 Circuit of Spa-Francorchamps, where Sebastian Vettel said: “I grew up with the Braun brand. We both come from the same state of Hesse, so the connection is deep rooted. I have always been amazed by how much technology goes into Braun shavers. It’s just like in Formula 1, the latest technology, the finest design and guaranteed durability. They simply do what you expect from them. I’m proud to be the ambassador for Braun male grooming.”

Braun’s Global Marketing Director, Lakis Vasileiadis, says “We are truly delighted to have Sebastian as our new ambassador. He is an impressive man who has achieved his dream through hard work, preparation, perseverance and the ultimate performance. He is a leader in his sports. Like Max Braun, our founder, Sebastian has relentlessly pursued his dream. He is an inspiration to millions of men and the ideal person to represent Braun.”

Technical breakthroughs always start with a Dream. Max Braun, the company’s founder, dreamt of creating the first electric foil shaver. And since then, BRAUN never stopped engineering dream innovation. BRAUN dreamt of designing the first “washing machine” for shavers, and later on about the first shaver that cools your skin. Today, these dreams are a reality the Braun Clean & Renew™ system and with the Braun °CoolTec.

BRAUN is inspired by men like Sebastian: a high achiever, who realised his dream to become the youngest Formula 1 champion ever. Vasileiadis continues: “We have a similar belief in and understanding of Dreaming. And we don’t just dream, we bring them to life. It is our aim to inspire others to realise their dreams too.”

Sebastian will be the face of the new BRAUN shaver’s campaign: “Hold on to your dreams”. Kicking off in Autumn 2013, together with Sebastian, BRAUN is calling on men around the world to never give up chasing their dreams.

# # #

About Braun

Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, manufactures a wide variety of small domestic appliances that marry innovation, reliability and creative design. These range from electric shavers and beauty products to hair care appliances. Braun products enjoy worldwide distribution. Please visit for the latest news and in-depth information about the Braun brand.

About Procter & Gamble

P&G serves approximately 4.8 billion people around the world with its brands. The Company has one of the strongest portfolios of trusted, quality, leadership brands, including Ace®, Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Duracell®, Fairy®, Febreze®, Fusion®, Gain®, Gillette®, Head & Shoulders®, Iams®, Lenor®, Mach3®, Olay®, Oral-B®, Pampers®, Pantene®, Prestobarba®, SK-II®, Tide®, Vicks®, Wella®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit for the latest news and in-depth information about P&G and its brands.

Photos/Multimedia Gallery Available:


Press Contacts:

For more information, please contact:

Emily Buckland

+44 (0) 7720 277 197

Liz Littlechild

+44 (0) 7989 968 997


Countries That Install Advanced Infrastructure System from Edison Global Circuits Could Be Eligible for Long-Term Country Infrastructure Funding from United Nations

ME NewsWire / BusinessWire

HOUSTON - Tuesday, August 27th 2013

Advanced Breaker/Meter Gateway System Helps Governments, Utility Companies in Emerging Markets Quickly Deliver Improved Communications to Citizens via Global Mobile Networks

After reviewing new multi-purpose gateway technology from Edison Global Circuits (EGC), United Nations representatives say it is not only advanced, affordable and quick to implement but that it most likely will qualify as “country infrastructure” and should be eligible for long-term funding, and the organization would be open to providing funding to any country that wants to install it.

EGC’s Advanced Infrastructure System (AIS) is a combination of communications, access, measurement & control, breaker development and customer interaction – all in one product – allowing any government that puts the advanced breaker/meter gateway system into production the capability to become a “smart country” rather quickly, saving – and generating – millions along the way.

“AIS is not a meter, but a multi-purpose gateway designed to interact with utility companies, customers, carriers and content providers. There are plenty of so-called smart meters out there, but none of them come close to what EGC has developed. AIS is not ‘smart,’ it’s genius,” said Stephen Williams, CEO of Houston-based EGC, a leading-edge pioneer in electrical safety and diagnostic systems. “It’s an 8-products-in-1 state-of-the-art multi-way communication, feature-rich, low-cost end point solution for governments and utilities around the world to upgrade their grid infrastructures, conserve energy and deliver higher-quality services to their populations, using, among others, cell tower systems already in place.” The advanced breaker/meter gateway system design team was headed by EGC engineer Jeff Franks, who invented the smoke detector in 1975 and is credited with bringing more than 20 products from design to market, several reaching billion-dollar sales marks.

“The United Nations recognizes that when countries add improvements to daily living, better living conditions lead to a more stable socioeconomic status and greater functionality in the global arena. When we met with representatives in Brussels to demo AIS, they were on board immediately,” said Ray Cole, EGC CFO. “Our advanced breaker technology has U.S. and international patents and creates an intelligent communication gateway for worldwide use. The patented technology adds price elasticity and an ability to control and monitor electrical impulse from any wiring system worldwide.”

More Information for Governments and Utilities:

The UN’s International Telecommunication Union estimates only 39% of the world has Internet access, which means 61% of all homes worldwide aren’t receiving basic Internet service. “Think about what providing basic services many of us take for granted – Internet, television, cable, banking, security, education – could mean for a household in an emerging market,” Cole said. “The AIS gateway technology allows governments a way to offer a variety of services at a low cost to its citizens, elevating their home lives with services from utilities and content providers that inform, educate and keep them safe.”

By comparison, a 2013 UN study showed that in a world of 7 billion people, 6 billion have access to mobile phones and it’s been estimated there will be more active cell phones in the world than people by 2014. Most emerging governments can’t afford or haven’t been able to build out their communication infrastructure pathways to keep up with growth, but commercial telecoms have met demand by building out large geographic areas with cell service.

“EGC has been focused on bringing our Smart Country Infrastructure SystemTM (SCIS) to billions of underserved populations in developing countries. AIS directly addresses lack of Internet usage in emerging markets, instead focusing on existing communications pathways and networks to help governments and utility companies deliver services to the home," Williams said. “We’ve basically eliminated the cost in time and resources a government would need to upgrade their communications infrastructure. The seamless multi-way communication makes it possible for any utility to provide Internet, TV, phone, security, educational services or really any application that can be delivered through existing networks to the home.”

Key Benefits to Governments and Utilities

   - AIS is the only product in the world that connects directly to the circuits already in the home, which means utilities can reduce theft up to 80% – that alone pays for the system.

   - A unique patented feature allows a utility company to shed load throughout their grid without shutting down individual homes, preventing brownouts or blackouts and conserves energy.

   - The AIS powerful gateway feature that allows carriers and content providers access without wiring the house or providing set-top boxes, also allows utility companies to share in these newly created revenue streams.

   - Fully deployed, implementing the AIS gateway in country can pay for the entire installation and maintenance of the system.

Key Features of the EGC Advanced Infrastructure System:

   - 7-inch touch screen offers interactive communications like energy-usage updates, emergency alerts and bill pay

   - Revolutionary patented life-saving breaker system and smart meter offers improved home safety and increased system control

   - 120-240V AC single pole 20-50 amp circuit breaker guards against overloading and short circuits in the home

   - Wi-Fi and 3G/4G module package allows third-party access and delivery of Internet, video and dial services

   - Proprietary gateway feature accepts all communications protocols and feeds data back to the provider, allowing any third party to connect to AIS and drive media to an end appliance, like a TV, using existing home electrical wiring

   - Meets and exceeds utility networking requirements

    Internal measurement and control system vital for utility data management and remote system controls

   - Completely downloadable state-of-the-art systems controller module allows for simple upgrades and cost effectiveness

   - Two-way communications allows utility to connect to AIS box to send and receive data through the internal meter to and from each individual plug-in breaker

   - Unique video and audio delivery provides revenue source for utility with no additional hard wiring while at the same time upgrading quality of services to its consumers


About Edison Global Circuits

Houston-based Edison Global Circuits, a leading-edge pioneer in electrical safety and diagnostic systems, provides proprietary solutions for safety, diagnostics, fire prevention, smart meters, green adaptations and true home and business gateways to the United States and countries all over the world. Via its revolutionary, next-generation utility and broadband communications platform Smart Country Infrastructure SystemTM, EGC works with emerging nations to help them improve their grid networks and reduce modernization costs, providing consulting services to area utilities to assist with updating the way they communicate with homes and businesses on their grids, with immediate return on investment. The company’s advanced breaker/meter gateway Advanced Infrastructure System is a state-of-the-art, low-cost solution for governments and utilities around the world.


Edison Global Circuits, Houston

Stephen Williams or Ray Cole, 832.813.8733


Christie Assure Program Expands Globally Revolutionizing VeinViewer Training for Healthcare Facilities

ME Newswire / Business Wire

MEMPHIS, Tenn. - Tuesday, August 27th 2013

Christie Medical Holdings, Inc., today announced the expansion of its industry-leading Christie Assure Program to hospitals and physician offices in over 40 countries using the HD VeinViewer® vein illumination products which project vascular imaging on the skin surface.

The five-year program includes warranty, access to online clinical education and an upgrade program to the latest Christie product platforms. An industry-first, the Christie Assure Program represents a significant leadership investment in seeing the end customer achieve utilization and results through Christie technologies.

Chris Schnee, GM and VP at Christie Medical Holdings, said, “We launched VeinViewerGS internationally in 2008. Today 3rd, 4th and 5th generation VeinViewers are being sold around the world. Through our technology leadership and support, we aim to help VeinViewer users achieve an increase in patient satisfaction, a potential reduction in patient risk and infection, and maximize healthcare economic benefits.”

The Christie Assure Program was built upon the results of a thorough survey where customers asked for help to achieve the same results which have proven the benefits of VeinViewer technology in clinical studies. Results show up to a 100 percent increase in first-stick success and patient satisfaction ratings and a 50 percent decrease in medically unnecessary PICC lines. The goal is to maximize the positive return each facility receives from its investment and to improve patient care.

Christie Assure Program terms apply.

Recently, the company’s three clinical studies encompassing 3,000 data points compared VeinViewer’s measurements to that of ultrasound, the industry gold standard. The studies, vetted and approved by Institutional Review Board (IRB) Services, demonstrated that VeinViewer measured accurate within half a millimeter on average, and for veins most commonly accessed for a peripheral IV (3mm-7mm wide), it projected near perfect vein widths (+/- 0.06mm).

VeinViewer has undergone ten stringent peer reviews since 2006. Third-party medical peer reviews demonstrate the statistically significant clinical effectiveness of VeinViewer, and often evaluate potential savings to the bottom line.

VeinViewer technology was developed with the aid of the engineering capabilities and resources of parent company Christie Digital Systems, a leading global visual technology firm with more than 80 years of experience in the projection systems industry. VeinViewer is the first and only device on the market to use: harmless near-infrared light, DLP® technologies, exclusive technology such as Active Vascular Imaging Navigation (AVIN™) providing the demanded Pre, During and Post-access (PDP) benefits, TrueView imaging accuracy in projected vein-widths which is three to ten times more accurate than competition, and technologies such as Df2 (Digital full field) to illuminate the only real-time HD digital image of subcutaneous vasculature and blood patterns directly onto the skin surface. Although designed for assistance in IV starts and blood draws, VeinViewer has proven beneficial in spider and varicose vein treatment.

To learn more about Christie product offerings please visit

About Christie Medical Holdings, Inc.

Christie Medical Holdings Inc. is a global company based in Memphis, Tenn., that discovers, develops and commercializes medical technologies. The company’s market-leading product, VeinViewer®, is a mobile vascular imaging system that allows health care providers to clearly see accessible vasculature as a real time HD image, directly on the surface of the skin. Christie Medical Holdings Inc. is owned by Christie Digital Systems Inc., a global visual technologies company and a subsidiary of Ushio Inc., Japan (JP:6925). For more information on Christie Digital Systems or Christie Medical Holdings, visit

Follow us on Twitter @veinviewer

DLP® is a registered trademark of Texas Instruments.


Christie Medical Holdings, Inc.

Carmen Robert, 519-572-5824


Monday, August 26, 2013

Quintiles Infosario Receives Computerworld Data+ Editor’s Choice Award

Recognizing data as a strategic asset

RESEARCH TRIANGLE PARK, N.C - Monday, August 26th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Quintiles has been recognized for its pioneering work creating big data solutions that help pharmaceutical organizations improve their probability of success throughout the drug development process, with a Computerworld Data+ Editor’s Choice Award for its Quintiles Infosario® platform.

"The drug development process is predicated upon the availability of high quality data with which to collaborate and make informed decisions at every step of the way during the evolution of a product or treatment," said Quintiles Chief Information Officer Richard Thomas. "We are delighted to receive this award which highlights the work of our outstanding team of dedicated professionals, partners and customers who all contributed in the development of technologies that power our Quintiles Infosario platform."

Quintiles Infosario is an end-to-end suite of technologies that power the pharmaceutical product development process. Making innovative use of advances in big data technologies, Infosario is able to break down silos combining massive quantities of scientific and operational data collected during clinical development with tens of millions of real-world patient medical records and population data. Empowering researchers and drug developers with the knowledge locked in this data improves decision making, and ultimately increases the probability of success at every step in a product’s lifecycle.

Computerworld’s Data+ awards recognize the very best projects that illustrate how big data can be mined and analyzed to predict trends and improve the probability of success. Honorees are being recognized in the August 26th issue of Computerworld, on and at Computerworld’s 2013 Data+ conference.

“The organizations honored in this year’s Data+ Editor’s Choice awards program have unearthed the business value that’s rooted throughout big data,” said Scot Finnie, editor in chief, Computerworld. “The projects spotlighted are tapping into big data to analyze and influence customer behavior, drive new business revenues and predict future trends. Each of the organizations is raising our understanding of big data to new levels, while at the same time opening the door for other organizations to follow their lead. It’s an exciting time in the big data field.”

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit

Click here to subscribe to Mobile Alerts for Quintiles.



Media Relations:

Phil Bridges, + 1-919-998-1653

Investor Relations:

Karl Deonanan, +1-919-998-2789


Nordson EFD's PICO xMOD Exchangeable/Modular Dispensing Valve Improves Productivity and Reduces Cost

EAST PROVIDENCE, R.I. - Monday, August 26th 2013 [ME NewsWire]

(BUSINESS WIRE) Nordson EFD, a Nordson company (NASDAQ: NDSN), introduces the PICO® xMOD™ Valve, a new and exciting fully exchangeable and modular concept in non-contact and contact needle dispensing of assembly fluids.

Nordson EFD’s PICO xMOD valve system technology uses high-tech, robust, durable piezoelectric actuation technology for continuous operation at speeds of up to 500 cycles/second. The PICO xMOD can produce deposits as small as 2 nanoliters, at high production speeds, with exceptional deposit accuracy and superior process control. The non-contact jet valve makes it possible to apply fluid in hard-to-access areas or onto uneven or delicate substrates for applications in electronics, automotive, life sciences, solar, and a range of other industrial dispensing applications.

All five major xMOD valve components – the Piezo Actuator (PA), the Valve Seat (VS), the Fluid Body (FB), the Cartridge ball/stem assembly (CR), and Heater Set (HS) – are fully interchangeable and easily assembled for each specific application and quickly disassembled for easy cleaning, repair, or maintenance. Each part can be removed and exchanged in seconds, eliminating production down-time and significantly increasing productivity.

“Our new PICO xMOD offers the only tool-free release and installation of the Valve Seat assembly,” explains Claude Bergeron, product line manager, Nordson EFD. “Wetted parts are conveniently and quickly exchanged and serviced. If a part fails, just the worn part needs changing, eliminating the expense of a whole new valve assembly. The ability to swap one xMOD component part for another lets the manufacturer toggle between different applications and fluids, offers flexibility, makes a significant reduction in production down time, and saves time and money.”

Each EFD PICO xMOD component can be individually selected to accommodate particular fluids and applications. All the components are engineered to work together as a complete, integrated system that produces exceptionally fast, accurate deposits of a wide range of fluids.

Industries and Applications for PICO xMOD Dispense Valve include:

Wireless and Display

    UV cure adhesives for bonding (camera modules, keypads, microspeakers, touch pads, and display edge sealing)
    Hydrophobic fluids for protective treatments
    COG (Chip on Glass) and TAB sealing


    UV adhesives on mobile speaker membranes
    Fluxes and conformal coatings

Life Sciences/Medical Devices

    Adhesives for bonding needles to hubs
    Bonding of disposable medical device components


    Oil and grease dispensing on electrical connectors, gears, and other small part assemblies
    Marking and color coding of parts with ink
    UV adhesive to bond automotive electronic components

Nordson EFD’s PICO xMOD uses the same precision and high quality parts as all Nordson EFD’s PICO valves, maintaining the same high level of dispensing repeatability and precision, while also adding the various benefits of modular exchangeability.

Photo of xMOD available at:

Animation of xMOD available at:

For more information, visit Nordson EFD on the web at,, or, email at, or call +1 401.431.7000 or 800.556.3484.

Nordson EFD’s PICO xMOD valve will be featured at the following global shows:




The Assembly Show

USA – Rosemont, IL

Oct. 28-30

Elexcon China

China – Shenzhen

Nov. 16-21


Europe – Munich

Nov. 12-15

About Nordson EFD

Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. EFD dispensing systems help companies in a wide variety of industries increase throughput, improve quality, and lower production costs. Additional fluid management capabilities include syringe barrels and cartridges for packaging one- and two-component materials and a wide variety of fittings, couplers and connectors for controlling fluid flow in medical, biopharmaceutical, and industrial environments. The company is a leading formulator of specialty solder pastes for dispensing and printing applications in the electronics industry.

About Nordson Corporation

Nordson Corporation (NASDAQ: NDSN) delivers precision technology solutions to help customers succeed worldwide. The company engineers, manufactures and markets differentiated products and systems used for dispensing adhesives, coatings, sealants, biomaterials and other materials, fluid management, test and inspection, UV curing and plasma surface treatment, all supported by application expertise and direct global sales and service. Nordson serves a wide variety of consumer non-durable, durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at, or


Nordson EFD

Rhonda Mitchell, +1 401-431-7065

Strategic Marketing Services Manager

A R Marketing, Inc. (agency)

+1 858-451-8666


ABThera™ Open Abdomen Negative Pressure Therapy System Study Published in World Journal of Surgery

Significantly Improved Patient Outcomes Using ABThera™ Negative Pressure Therapy System in Open Abdomen Surgery

SAN ANTONIO - Monday, August 26th 2013 [ME NewsWire]

(BUSINESS WIRE) Kinetic Concepts, Inc. announced today that results of the observational study, “Prospective Study Examining Clinical Outcomes Associated with a Negative Pressure Wound Therapy System and Barker’s Vacuum Packing Technique” is published in the September 2013 print edition of the World Journal of Surgery.1 These results, published online in May 2013, showed that ABThera™ Open Abdomen Negative Pressure Therapy System (ABThera™ OA NPT) was associated with significantly improved patient outcomes compared to traditional Barker’s vacuum-packing technique (BVPT) in trauma and surgical patients studied.

“Used as part of a comprehensive approach to open abdomen management, ABThera™ OA NPT was associated with a significantly lower mortality rate, increased abdominal closure rate and improved overall patient outcome,” said Michael Cheatham, MD, Corporate Chairman of Surgery, Orlando Health, and lead author of the study.

In the ABTAC study, 280 trauma and surgical patients who required temporary abdominal closure (TAC) following a damage control laparotomy or treatment of either intra-abdominal hypertension or severe sepsis, were enrolled from 20 sites across the US. Among patients treated with at least 48 hours of consistent TAC therapy (ABThera™ OA NPT n=111; BVPT n=57), the rate of primary fascial closure within 30 days was 69 percent for the ABThera™ OA NPT group and 51 percent for the BVPT (p=0.03). In this same patient group, the 30-day all-cause mortality rate was 14 percent for patients treated with ABThera™ OA NPT and 30 percent for those treated with BVPT (p=0.01). Multivariate logistic regression analysis identified that patients treated with ABThera™ Therapy were 3.2 times more likely to survive up to 30 days compared to BVPT patients [(95 percent confidence interval); p=0.02] after controlling for age, severity of illness and cumulative fluid administration.

“These dramatic and highly significant results underscore the value of ABThera™ Therapy in improving the management of patients with an open abdomen, a complex and often life-threatening condition,” said Ron Silverman, MD, chief medical officer, KCI.

The ABThera™ Open Abdomen Negative Pressure Therapy System is indicated for temporary bridging of abdominal wall openings where primary closure is not possible and repeat abdominal entries are necessary. This system is intended for use in open abdominal wounds with exposed viscera including, but not limited to, abdominal compartment syndrome. The intended care setting is a closely monitored area within the acute care hospital, such as the ICU. The abdominal dressing will most often be applied in the operating theater.

For more information about the ABThera™ Open Abdomen Negative Pressure Therapy System, including important safety information, please visit To access the online version of the article, please click here.

About KCI

KCI is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 65 countries around the world. Headquartered in San Antonio, Texas, KCI is committed to advancing the science of healing and positively affecting patient care by developing customer-driven innovations to meet the evolving needs of healthcare professionals. Proprietary KCI negative pressure technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C.® Therapy System has been used on more than 7 million wounds worldwide. Additional information about KCI and its products is available at

1Cheatham ML, Demetriades D, Fabian TC, et al. Study Examining Clinical Outcomes Associated with a Negative Pressure Wound Therapy System and Barker’s Vacuum Packing Technique. World Journal of Surgery. 2013 September; 37(9):2018-2030

KCI Corporate Communications
Mike Barger, 210-255-6824


ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa in various atrial fibrillation patient populations

ME Newswire/ Business Wire

INGELHEIM, Germany - Monday, August 26th 2013

For media outside of the US, the UK & Canada only

Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised by the European Society of Cardiology (August 31 – September 4, Amsterdam, The Netherlands). The new data will add to the already available extensive body of knowledge on Pradaxa®’s positive safety and efficacy profile.

Boehringer Ingelheim remains committed to advancing the cardiology field and supporting physicians in their search for optimal stroke protection. Data being presented at the ESC Congress 2013 will complement the ongoing clinical trial programme of Pradaxa®, including results from the pivotal RE-LY® trial and the only long-term NOAC study, RELY-ABLE®, as well as new preclinical research on the company’s investigational antibody fragment antidote for dabigatran.

“The breadth of data being presented for Pradaxa® at this year’s ESC Congress 2013 demonstrates Boehringer Ingelheim’s continued dedication to improving the lives of patients with cardiovascular disorders. Our extensive and ongoing investment into clinical research will provide additional evidence on the positive efficacy and safety profile of Pradaxa® as well as important insights on its use in a wide range of patients and clinical settings”, said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim.

Details of the key Pradaxa® abstracts being presented at the ESC Congress 2013 are listed below. Further information and the full list of abstracts can be found within the Scientific Programme, available at:




Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY

Robby Nieuwlaat (Hamilton, CA)

Poster Presentation ESC Number: P549 Poster Session 1: Arrhythmias – Pacing – Resynchronisation Date: 31 August Display Time: 14:00-18:00 Presentation Time: 15:30-16:30 Location: Posters – Village 9

Effects of the direct thrombin inhibitor dabigatran etexilate vs warfarin on platelet function in patients with atrial fibrillation

Giulia Renda (Chieti, IT)

Poster Presentation ESC Number: P1430 Poster Session 2: Treatment of Hypertension Date: 1 September Display Time: 08:30-12:30 Presentation Time: 10:00-11:00 Location: Posters – Village 9

RE-ALIGN: Dabigatran in patients with a mechanical heart valve

Frans Van de Werf (Leuven, BE)

Hot Line Presentation ESC Number: 937 Hot Line 1: Late Breaking Trials on Thrombosis Date: 1 September Time: 11:54-12:06 Location: Amsterdam – Central Village

Guidance adherent dabigatran etexilate treatment versus warfarin in the RE-LY population: an analysis on the basis of the European label recommendations for dabigatran etexilate

Gregory Y H Lip (Birmingham, GB)

Poster Presentation ESC Number: P4278 Poster Session 5: Atrial Fibrillation: New Insights Date: 2 September Display Time: 14:00-18:00 Presentation Time: 15:30-16:30 Location: Posters – Village 9

Reversal of dabigatran clotting activity in the rat ex vivo by a specific and selective antibody fragment antidote: are there non-specific effects on warfarin, rivaroxaban and apixaban?

Joanne Van Ryn (Biberach, DE)

Poster Presentation ESC Number: P4848 Poster Session 6: Thrombosis and Antithrombotic Therapy Date: 3 September Display Time: 08:30-12:30 Presentation Time: 10:00-11:00 Location: Posters – Village 9

Pradaxa® is widely approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for primary prevention of VTE following total hip replacement or total knee replacement surgery.1 The extensive in-market experience of over 2 million patient-years in all licensed indications puts Pradaxa® first among the novel oral anticoagulants.2 In addition, Boehringer Ingelheim recently started submitting applications to regulatory authorities for the use of Pradaxa® in the acute treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism.

Please click on the link below for ‘Notes to Editors’ and ‘References’:


Boehringer Ingelheim GmbH

Sara McClelland

Corporate Communications

Media + PR

Phone: +49 6132 – 77 8271



More information